Bristol's Yervoy, alone or in combo, improves melanoma results: studies

(Reuters) - New data on Bristol-Myers Squibb Co's melanoma drug Yervoy, including fresh results from an effort to combine it with another promising cancer immunotherapy, suggest it can improve treatment for patients with both advanced and slightly earlier stage disease, according to findings released on Monday.

via Reuters: Health News Read More Here..